Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
Scientific Congress Publications
Supported by Bayer Pharmaceuticals
WSC 2026
ASUNDEXIAN FOR SECONDARY STROKE PREVENTION IN CHINESE PARTICIPANTS IN EAST ASIA: SUBGROUP ANALYSIS OF THE OCEANIC-STROKE TRIAL
To evaluate the efficacy and safety profile of asundexian among Chinese participants (self-defined) in East Asia in the OCEANICSTROKE trial.
Chinese participants were younger, more likely to be male, and have previous stroke, diabetes, current tobacco use, and small vessel occlusion subtype index strokes, when compared descriptively with the overall OCEANIC-STROKE population. Chinese participants were less likely to be treated with IVT or EVT.
Among Chinese participants with acute noncardioembolic ischemic stroke or highrisk TIA, asundexian added to antiplatelet therapy reduced ischemic stroke occurrence compared with antiplatelet therapy alone, without increasing the risk of ISTH major bleeding. Treatment effects were generally consistent across prespecified subgroups.
© 2026 Bayer. All rights reserved.
Bayer and the Bayer Cross are registered trademarks of Bayer.
Copies of the Bayer Pharmaceuticals supported presentations obtained from this platform are for personal use only and may not be reproduced or distributed without permission from the authors.
Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities, and the presentations are shared in the interest of scientific exchange.
For any questions, please contact Medical Information at https://www.medicalinformation.bayer.com/
PP-GEN-ALL-0014-1
